Synaptic Corporation : A Case Study Of Risk

Nissan Motor Company was one of the first Japanese Automobile companies to build facilities in North America. The company was reborn from crisis. They were rescued from bankruptcy in 1999 by Renault, and this sense of crisis still persists in the organization to this day. After the 9.0 magnitude earthquake hit the coast of Japan on March 11, 2011 Nissan Motor Company, just like they did in 1999 when they faced financial difficulties, focused on identifying and analyzing the risks by establishing a dedicated risk management function that was responsible for these activities.

IT projects can have a lot of different components to them which creates the potential for more risks. These risks need to be identified, analyzed, and addressed as the project progresses (Schwalbe Ph.D., 2014). There are different types of risk that can affect the implementation of a system that will allow people to manage their own human resource information. A positive risks can produce a project under budget or ahead of schedule, while a negative risks can have adverse effects on a project such as going way over budget. There are also some risks that do not have a positive or negative impact on a project. Identifying risks and addressing them is mostly handled by the program manager.

An innocent child is standing in a candy store and looking at all his favorite options from which to choose. He slowly reaches for the bag of M&Ms, and he does not know what all the chemicals in that bag will cause him. The M&Ms have ADHD (Attention Deficit Hyperactivity Disorder) causing carcinogens in them called food dyes. These food additives help the food products stay vibrant and eye catching but America’s youth does not know what the consequences are when you eat these products. Children think they are nice and colorful but they do not know what lies behind the wonderful rainbow of colored M&Ms in that bag. That is why The United States needs to ban food color additives to make our nation healthier. The main points on food dyes are the problems they cause, the counter argument against them and the steps the country can take to solve these problems.

However, when IT projects fall behind schedule, these efficiencies can quickly evaporate and lead to cost overruns, glitches and bugs. (3) Due to their inherently complex nature, IT projects are susceptible to many types of failures; mainly caused by a lack or risk management and flexibility. Many of the risks present in IT projects are unrealistic goals; inaccurate estimates of needed resources; badly defined system requirements; poor reporting of the project’s status; poor communication between developers and users; adoption of immature technology; inability to cope with project complexity; sloppy developed practices; mismanagement of the project; stakeholder politics; and commercial pressures. (4) With so many potential risks, it is not surprising that IT projects that are completed on time, and on budget, are more the exception rather than the rule. Additionally, before IT projects begin, clear objectives and the allocation of time and resources need to be defined; all of which are usually lacking for one reason or another. The result is a high failure rate associated with IT projects overall, which puts a spot light on the need for organizations to improve their risk management abilities and design processes that will allow them the flexibility to reallocate resources when unexpected problems when they

Synaptic is a bio technology company that uses a combination of both Information Management (IM) and biological research to develop drugs based on proteins and peptides. Synaptic is comprised of a large Information Management department which consists of multiple divisions within the department. Each division within the IM is in charge of communications and computer systems services, in particular research, manufacturing and infrastructure. The company also employs computational scientists that aid with the research aspect of the product development. The development of the product makes it necessary for both set of parties – the Information Management and the scientists to interact with each

Pather, S., Remenyi, B., & Remenyi, D. (2011). Managing risks of ICT projects. Kidmore End: Academic Publishing.

This presentation can be applied to biology as the majority of print regarding biology is moving to digital sources. For example, the large majority of research projects are maintained in online databases that allow for accessible storage, organization, and the ability to quickly scan to find the topic of interest. Thus a current application of this would be the transition of college lab reports and research documentation to digital sources. Another way this presentation could apply to the biology is the way in which biologists collaborate on research. Furthermore, technology has led to significant changes in the way biologists communicate, this is particularly meaningful for science given that the production of scientific knowledge is fundamentally a social process involving information sharing, collaboration and the mobilization of outputs. Additionally, applications such as cloud computing have the potential to change the system of collaboration further by making the process of sharing and multi-authoring documents much easier and by placing ideas within a “social” context to allow even more people to contribute. Thus the technological applications within biology are endless and it has the potential to completely change the way in which biology is studied, taught, and

The book “from Alchemy to IPO the business of Biotechnology” is a synopsis of the biotech industry from its inception to late 1900’s . Author Cynthia Robbins – Roth writes a first hand narration from amidst the blooming industry as she was one of the first senior scientist to be recruited by Genentech. The book gives a complete picture from the roots of biotech , the major milestones achieved and the process of getting the product out to the market. It also covers the financers, venture capitalist and the common man’s view of the biotech industry from time to time, during its progression.

Amgen Inc. is a biotech company. The responsibilities of the Product Development Teams (PDT’s) can be described as “discretionary cost centres”. The output of a PDT is therefore difficult to relate to its input. Based on the long-term

Amgen Inc. is a biotech company. The responsibilities of the Product Development Teams (PDT’s) can be described as “discretionary cost centres”. The output of a PDT is therefore difficult to relate to its

In order to decide on the R&D portfolio, an objective quantitative analysis might not be suitable considering the high levels of uncertainities and consequently the risks involved in pharmaceutical research projects. It is important to have a qualitative analysis of the situation as a whole that includes Vertex’s own financial position, strategic implications, a quantitative analysis of its Portfolios with realistic estimations and a risk analysis of the portfolios.

Achieve a median composite eight-year product development cycle by 2010. Deliver two new molecular entity (NME) launches on average per year from 2010. In order to achieve the above objective, ensure that we have 10 or more NMEs in Phase III development by 2010. Development cycle times and quality for small molecules and biologics. Number of NME launches per year. Attrition rates. Number of development projects by phase. Number of in-licensing deals, alliances and acquisitions. R&D investment levels. Improving R&D quality and speed through leading-edge science, effective risk management and decision-making and overall business efficiency. Maximising the value of our biologics business and continuing to build a major presence in this fast-growing sector. Investing in external opportunities to enhance our internal innovation through in-licensing, alliances and acquisitions. 2008 target exceeded for small molecule development cycle times. NME and life-cycle management progressions

First, it takes an extremely long time to develop a new drug, and only a very small portion of all projects is successful. Projects that the company starts today will determine its financial performance 10-15 years later. Therefore, careful planning of R&D projects is very important for the long-term stability of the company.

Design a process to identify and analyze the nature, source and scale of any significant risks or uncertainties faced by Apple Inc.

Although R&D has been retained by the large pharmaceutical firms, there has been a continuous decline in the R&D productivity. Controlling R&D is imperative to the success of a Pharmaceutical firm. However, as the pharmaceutical industry is maturing, there are diminishing returns to the R&D investment. Fewer and fewer blockbuster drugs are being discovered and therefore R&D is not the most value adding component in the value